Clinical trials: Vinorelbine
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer.
- Trial name
- NCT01196078
- Testing
- erlotinib [Tarceva], vinorelbine
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Non-small-cell Lung Cancer
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
The purpose of this study is to evaluate the overall response rate and disease free survival for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation.
- Trial name
- NCT01843647
- Testing
- Icotinib, Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
This study mainly to observe the anti angiogenic drugs Endostatin (Endostar) combined with vinorelbine and Cisplatin (NP) as neoadjuvant therapy in patients with non small cell lung cancer clinical efficiency and safety.
- Trial name
- NCT02497118
- Testing
- Endostatin, Vinorelbine, Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
To evaluate the efficacy of metronomic oral vinorelbine taken three times a week without break plus bevacizumab as salvage treatment in patients with metastatic breast cancer.
- Trial name
- NCT00694200
- Testing
- Vinorelbine, Bevacizumab
- Where
- 9 sites in Greece
- Volunteers
- 13 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.
- Trial name
- OVINTRA (NCT01242449)
- Testing
- Trastuzumab, Vinorelbine
- Where
- 3 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- Vejle Hospital
Lung Cancer, Non Small Cell Lung Carcinoma
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes.
- Conditions
- Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
- Trial name
- NCT01209520
- Testing
- Cisplatin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of…
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00337194
- Testing
- monoclonal antibody SGN-30, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01196559
- Testing
- Vinorelbine and Gemcitabine
- Where
- 4 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- The Catholic University of Korea
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-2 (NCT01683682)
- Testing
- BIBF 1120, Vinorelbine, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Prostate Cancer
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
Purpose: This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of hormone refractory prostate cancer.
- Trial name
- NCT00151086
- Testing
- Estramustine, Vinorelbine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan Rogel Cancer Center
Non Small Cell Lung Cancer
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
A sub-population of patients affected by non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) do not gain benefit from treatment with tyrosine-kinase inhibitors (TKIs).
- Trial name
- NCT02319577
- Testing
- oral vinorelbine, Gefitinib
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Non Small Cell Lung Cancer
First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome.
- Trial name
- Lung-TRIO (NCT01038037)
- Testing
- Carboplatin, Vinorelbine, panitumumab
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- Vejle Hospital
Non Small Cell Lung Cancer
Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
The investigators hypothesized that NSCL patients receiving therapy based on their baseline tumor markers levels would attain higher response rates than patients in the control arm receiving non customized therapy.
- Trial name
- CONTEST (NCT01784549)
- Testing
- Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
- Where
- Italy
- Volunteers
- 168 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Metastatic Breast Cancer, HER2 Positive
Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy, Failure or Contraindication of Trastuzumab Therapy
- Trial name
- CELAVIE (NCT01238029)
- Testing
- Lapatinib and Capecitabine and Vinorelbine
- Where
- 11 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Sponsor GmbH
Stage Ib Lung Carcinoma
Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma
Researchers developed the nomogram which evaluate the risk of recurrence after surgical resection, and found that the stage 1 NSCLC patients with more than 104 point of nomogram showed similar recurrence rate to the recurrence…
- Trial name
- NCT02281708
- Testing
- vinorelbine plus cisplatin
- Where
- South Korea
- Volunteers
- 1,012 people
- Sponsor
- Seoul National University Hospital
Hodgkin Disease
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Patients with 3 or more adverse prognostic factors have a higher relapse rate. Significant anti-tumor activity in Hodgkin's lymphoma has been reported with two new drugs:gemcitabine and vinorelbine.
- Trial name
- NCT00225173
- Testing
- Doxorubicin, Vinblastine, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Non-small Cell Lung Cancer Stage Ⅱ, Non-small Cell Lung Cancer Stage ⅢA
Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection
The purpose of this study is to evaluate S1 capsule plus Cisplatin as adjuvant treatment in stageⅡ and Ⅲa non-small cell lung cancer.
- Trial name
- S1VSNP (NCT02223611)
- Testing
- S1 capsule, Vinorelbine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Non Small Cell Lung Carcinoma
Chemoradiotherapy in Patients With Localised Lung Cancer
The study compares 2 different methods of combined chemotherapy and radiotherapy for the treatment of localised lung cancer in patients not suitable for surgery. Hypothesis(es) to be tested: 1.
- Trial name
- NCT00193921
- Testing
- Vinorelbine, High dose Radiotherapy, Gemcitabine
- Where
- 8 sites in Australia
- Volunteers
- 82 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Brain and Central Nervous System Tumors, Neuroblastoma
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating children with recurrent or…
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00003234
- Testing
- vinorelbine tartrate
- Where
- 228 sites in United States, Australia and 5 more
- Volunteers
- 50 people
- Sponsor
- Children's Oncology Group
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University